A TPS integrated machine learning tool for predicting patient-specific quality assurance outcomes in volumetric-modulated arc therapy

•Selection of a machine learning classification model for PSQA results.•Full integration into the treatment planning system.•Decision-support tool, designed to be user-friendly.•Insight into the complexity of plans to identify and correct suboptimal plans. Machine learning (ML) models have been demonstrated to be beneficial for optimizing the workload of patient-specific quality assurance (PSQA). Implementing them in clinical routine frequently requires third-party applications beyond the treatment planning system (TPS), slowing down the workflow. To address this issue, a PSQA outcomes predictive model was carefully selected and validated before being fully integrated into the TPS. Nine ML algorithms were evaluated using cross-validation. The learning database was built by calculating complexity metrics (CM) and binarizing PSQA results into “pass”/“fail” classes for 1767 VMAT arcs. The predictive performance was evaluated using area under the ROC curve (AUROC), sensitivity, and specificity. The ML model was integrated into the TPS via a C# script. Script-guided reoptimization impact on PSQA and dosimetric results was evaluated on ten VMAT plans with “fail”-predicted arcs. Workload reduction potential was also assessed. The selected model exhibited an AUROC of 0.88, with a sensitivity and specificity exceeding 50 % and 90 %, respectively. The script-guided reoptimization of the ten evaluated plans led to an average improvement of 1.4 ± 0.9 percentage points in PSQA results, while preserving the quality of the dose distribution. A yearly savings of about 140 h with the use of the script was estimated. The proposed script is a valuable complementary tool for PSQA measurement. It was efficiently integrated into the clinical workflow to enhance PSQA outcomes and reduce PSQA workload by decreasing the risk of failing QA and thereby, the need for repeated replanning and measurements.